 CARLSBAD, Calif., July 14, 2021 GLOBE NEWSWIRE -- Qualigen Therapeutics, Inc. NASDAQ: QLGN, a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA for Qualigens QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses. 